Choong Gon Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Choong Gon Choi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ho Sung Kim
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
8 shared publications - Sang Joon Kim
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
8 shared publications - Chong Hyun Suh
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
7 shared publications - Seung Chai Jung
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
6 shared publications - Ji Eun Park
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
3 shared publications - Dae Chul Suh
Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2021
- Published by XMLink in Korean Journal of Radiology
- Vol. 22 (11) , 1875-1885
Neuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis
Kim PH, et al. Korean J Radiol. 2021 Jul;22:e86. https://doi.org/10.3348/kjr.2021.0127
- 1 January 2021
- Published by XMLink in Korean Journal of Radiology
- Vol. 22 (11) , 1875-1885
Open AccessNeuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis
Kim PH, et al. Korean J Radiol. 2021 Jul;22:e86. https://doi.org/10.3348/kjr.2021.0127
- 1 July 2020
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 2 (4) , e190083
Comparative Value of 2-Hydroxyglutarate–to–Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas
The 2-hydroxyglutarate (2HG)–to–lipid and lactate ratio is more accurate than the 2HG concentration alone for predicting isocitrate dehydrogenase mutation status in patients with glioma. Purpose To compare the ability of 2-hydroxyglutarate (2HG)–to–lipid and lactate (2HG/[lipid + lactate]) ratio with the ability of 2HG concentration alone to predict the isocitrate dehydrogenase (ID...
- 1 July 2020
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 2 (4) , e190083
Comparative Value of 2-Hydroxyglutarate–to–Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas
The 2-hydroxyglutarate (2HG)–to–lipid and lactate ratio is more accurate than the 2HG concentration alone for predicting isocitrate dehydrogenase mutation status in patients with glioma. Purpose To compare the ability of 2-hydroxyglutarate (2HG)–to–lipid and lactate (2HG/[lipid + lactate]) ratio with the ability of 2HG concentration alone to predict the isocitrate dehydrogenase (ID...
- Open Access
- 1 January 2020
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 21 (4) , 471-482
Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
Suh CH, et al. Korean J Radiol. 2020 Feb;21:e36. https://doi.org/10.3348/kjr.2019.0839
- 1 January 2020
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 21 (4) , 471-482
Open AccessOptimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials
Suh CH, et al. Korean J Radiol. 2020 Feb;21:e36. https://doi.org/10.3348/kjr.2019.0839
- Open Access
- 1 January 2020
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 21 (2) , 228-235
Alpha Stent for Coiling of Unruptured, Wide-Necked, Distal Internal Carotid Artery Aneurysms: Safety and Effectiveness at 6 Months
Song Y, et al. Korean J Radiol. 2019 Oct;20:e88. https://doi.org/10.3348/kjr.2019.0188
- 1 January 2020
- Published by The Korean Society of Radiology in Korean Journal of Radiology
- Vol. 21 (2) , 228-235
Open AccessAlpha Stent for Coiling of Unruptured, Wide-Necked, Distal Internal Carotid Artery Aneurysms: Safety and Effectiveness at 6 Months
Song Y, et al. Korean J Radiol. 2019 Oct;20:e88. https://doi.org/10.3348/kjr.2019.0188
- 1 August 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 292 (2) , 440-446
Primary Central Nervous System Lymphoma: Diagnostic Yield of Whole-Body CT and FDG PET/CT for Initial Systemic Imaging
Contrast-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose PET/CT as an initial staging modality for suspected primary central nervous system lymphoma should be ... Background Updated guidelines for suspected primary central nervous system lymphoma (PCNSL) are lacking. Purpose To investigate the diagnostic yield of initial systemic imaging in patients suspecte...
- 1 August 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 292 (2) , 440-446
Primary Central Nervous System Lymphoma: Diagnostic Yield of Whole-Body CT and FDG PET/CT for Initial Systemic Imaging
Contrast-enhanced chest and abdominopelvic CT and/or whole-body fluorine 18 fluorodeoxyglucose PET/CT as an initial staging modality for suspected primary central nervous system lymphoma should be ... Background Updated guidelines for suspected primary central nervous system lymphoma (PCNSL) are lacking. Purpose To investigate the diagnostic yield of initial systemic imaging in patients suspecte...
- 1 June 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 291 (3) , 752-762
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis
In patients with isocitrate dehydrogenase wild-type glioblastoma, necrosis of more than 20% was associated with a greater rate of false-positive measurement of 2-hydroxyglutarate with MR spectroscopy. BackgroundIsocitrate dehydrogenase (IDH) mutation has become one of the most important prognostic biomarkers in glioma management. Measurement of 2-hydroxyglutarate (2HG) with MR spectroscopy has shown high pooled sensitivity, although false-positive results with MR spectroscopy have been reported.PurposeTo investigate factors associated with false-positive 2HG measurements at MR spectroscopy in patients with IDH wild-type glioblastoma.Materials and MethodsThis retrospective study was approved by the institutional review board, and informed consent was waived. Consecutive patients with histopathologically confirmed pre- and posttreatment glioblastoma were evaluated between December 2017 and August 2018. Spectroscopy parameters, including 2HG measurements, were obtained with single-voxel point-resolved spectroscopy, and apparent diffusion coefficient (ADC) values were calculated. Necrosis was graded according to the proportion of necrosis within a volume of interest. Poisson regression analyses were perfor...
- 1 June 2019
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 291 (3) , 752-762
False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis
In patients with isocitrate dehydrogenase wild-type glioblastoma, necrosis of more than 20% was associated with a greater rate of false-positive measurement of 2-hydroxyglutarate with MR spectroscopy. BackgroundIsocitrate dehydrogenase (IDH) mutation has become one of the most important prognostic biomarkers in glioma management. Measurement of 2-hydroxyglutarate (2HG) with MR spectroscopy has shown high pooled sensitivity, although false-positive results with MR spectroscopy have been reported.PurposeTo investigate factors associated with false-positive 2HG measurements at MR spectroscopy in patients with IDH wild-type glioblastoma.Materials and MethodsThis retrospective study was approved by the institutional review board, and informed consent was waived. Consecutive patients with histopathologically confirmed pre- and posttreatment glioblastoma were evaluated between December 2017 and August 2018. Spectroscopy parameters, including 2HG measurements, were obtained with single-voxel point-resolved spectroscopy, and apparent diffusion coefficient (ADC) values were calculated. Necrosis was graded according to the proportion of necrosis within a volume of interest. Poisson regression analyses were perfor...
- Open Access
- 16 August 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (9) , 1643-1649
MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis
BACKGROUND: Accurate diagnosis of tumefactive demyelinating lesions is clinically important to avoid unnecessary invasive biopsy or inappropriate treatment. PURPOSE: We aimed to evaluate conventional and advanced MR imaging findings of tumefactive demyelinating lesions and determine the diagnostic performance of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor. DATA SOURCES: A systematic search of Ovid MEDLINE and EMBASE up to December 6, 2017, was conducted. STUDY SELECTION: Original articles describing MR imaging findings in patients with tumefactive demyelinating lesions were selected. DATA ANALYSIS: The pooled incidences of conventional MR imaging findings of tumefactive demyelinating lesions were obtained with the DerSimonian and Liard random-effects model. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were obtained using the bivariate random-effects model. DATA SYNTHESIS: Nineteen eligible studies with 476 patients with tumefactive demyelinating lesions were included. The pooled incidence of open ring or incomplete rim enhancement was 35% (95% CI, 24%–47%), which was significantly higher than the incidence of closed ring or complete rim enhancement (18% [95% CI, 11%–29%]; P = .0281). The pooled incidences of T2 hypointense rim, absent or mild mass effect, and absent or mild perilesional edema were 48%, 67%, and 57%, respectively. On advanced MR imaging, tumefactive demyelinating lesions showed a high apparent diffusion coefficient, peripheral restricted diffusion, and low cerebral blood volume. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were 89% (95% CI, 82%–93%) and 94% (95% CI, 89%–97%), respectively. LIMITATIONS: Seventeen of 19 studies were retrospective studies. CONCLUSIONS: Conventional MR imaging findings may help differentiate tumefactive demyelinating lesions from primary brain tumor, though further study is needed to determine the added value of advanced MR imaging.
- 16 August 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (9) , 1643-1649
Open AccessMRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis
BACKGROUND: Accurate diagnosis of tumefactive demyelinating lesions is clinically important to avoid unnecessary invasive biopsy or inappropriate treatment. PURPOSE: We aimed to evaluate conventional and advanced MR imaging findings of tumefactive demyelinating lesions and determine the diagnostic performance of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor. DATA SOURCES: A systematic search of Ovid MEDLINE and EMBASE up to December 6, 2017, was conducted. STUDY SELECTION: Original articles describing MR imaging findings in patients with tumefactive demyelinating lesions were selected. DATA ANALYSIS: The pooled incidences of conventional MR imaging findings of tumefactive demyelinating lesions were obtained with the DerSimonian and Liard random-effects model. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were obtained using the bivariate random-effects model. DATA SYNTHESIS: Nineteen eligible studies with 476 patients with tumefactive demyelinating lesions were included. The pooled incidence of open ring or incomplete rim enhancement was 35% (95% CI, 24%–47%), which was significantly higher than the incidence of closed ring or complete rim enhancement (18% [95% CI, 11%–29%]; P = .0281). The pooled incidences of T2 hypointense rim, absent or mild mass effect, and absent or mild perilesional edema were 48%, 67%, and 57%, respectively. On advanced MR imaging, tumefactive demyelinating lesions showed a high apparent diffusion coefficient, peripheral restricted diffusion, and low cerebral blood volume. The pooled sensitivity and specificity of MR imaging for differentiating tumefactive demyelinating lesions from primary brain tumor were 89% (95% CI, 82%–93%) and 94% (95% CI, 89%–97%), respectively. LIMITATIONS: Seventeen of 19 studies were retrospective studies. CONCLUSIONS: Conventional MR imaging findings may help differentiate tumefactive demyelinating lesions from primary brain tumor, though further study is needed to determine the added value of advanced MR imaging.
- Open Access
- 12 July 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (8) , 1439-1445
Clinically Relevant Imaging Features forMGMTPromoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis
BACKGROUND: O6-methylguanine methyltransferase (MGMT) promoter methylation status has been reported as a prognostic biomarker in clinical trials. PURPOSE: Our aim was to systematically evaluate imaging features of MGMT promoter methylated glioblastoma and to determine the diagnostic performance of MR imaging for prediction of MGMT promoter methylation in patients with newly diagnosed glioblastoma. DATA SOURCES: A computerized search of Ovid MEDLINE and EMBASE up to February 27, 2018, was conducted. STUDY SELECTION: We selected studies evaluating imaging features of MGMT promoter methylated glioblastoma and the diagnostic performance of MR imaging for prediction of MGMT promoter methylation. DATA ANALYSIS: Pooled estimates of sensitivity and specificity were calculated using a hierarchic logistic regression model. Meta-regression and sensitivity analysis were performed. DATA SYNTHESIS: Twenty-two articles including 2199 patients were included. MGMT promoter methylated glioblastoma is likely to show less edema, high ADC, and low perfusion. Ten articles including 753 patients were included in the meta-analysis. The summary sensitivity was 79% (95% CI, 72%–85%), and the summary specificity was 78% (95% CI, 71%–84%). In the meta-regression, MGMT promoter methylation and mean age were associated with heterogeneity. Sensitivity analysis excluding 1 study resolved the heterogeneity. LIMITATIONS: Included studies used a variety of different MR imaging techniques to predict MGMT promoter methylation. CONCLUSIONS: MGMT promotor methylated glioblastoma is likely to show less aggressive imaging features than MGMT promotor unmethylated glioblastoma. Despite the variety of different MR imaging techniques used, MR imaging in patients with newly diagnosed glioblastoma was shown to have the potential to predict MGMT promoter methylation noninvasively.
- 12 July 2018
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 39 (8) , 1439-1445
Open AccessClinically Relevant Imaging Features forMGMTPromoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis
BACKGROUND: O6-methylguanine methyltransferase (MGMT) promoter methylation status has been reported as a prognostic biomarker in clinical trials. PURPOSE: Our aim was to systematically evaluate imaging features of MGMT promoter methylated glioblastoma and to determine the diagnostic performance of MR imaging for prediction of MGMT promoter methylation in patients with newly diagnosed glioblastoma. DATA SOURCES: A computerized search of Ovid MEDLINE and EMBASE up to February 27, 2018, was conducted. STUDY SELECTION: We selected studies evaluating imaging features of MGMT promoter methylated glioblastoma and the diagnostic performance of MR imaging for prediction of MGMT promoter methylation. DATA ANALYSIS: Pooled estimates of sensitivity and specificity were calculated using a hierarchic logistic regression model. Meta-regression and sensitivity analysis were performed. DATA SYNTHESIS: Twenty-two articles including 2199 patients were included. MGMT promoter methylated glioblastoma is likely to show less edema, high ADC, and low perfusion. Ten articles including 753 patients were included in the meta-analysis. The summary sensitivity was 79% (95% CI, 72%–85%), and the summary specificity was 78% (95% CI, 71%–84%). In the meta-regression, MGMT promoter methylation and mean age were associated with heterogeneity. Sensitivity analysis excluding 1 study resolved the heterogeneity. LIMITATIONS: Included studies used a variety of different MR imaging techniques to predict MGMT promoter methylation. CONCLUSIONS: MGMT promotor methylated glioblastoma is likely to show less aggressive imaging features than MGMT promotor unmethylated glioblastoma. Despite the variety of different MR imaging techniques used, MR imaging in patients with newly diagnosed glioblastoma was shown to have the potential to predict MGMT promoter methylation noninvasively.
- Open Access
- 22 September 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (12) , 2245-2250
Comparison of High-Resolution MR Imaging and Digital Subtraction Angiography for the Characterization and Diagnosis of Intracranial Artery Disease
BACKGROUND AND PURPOSE: High-resolution MR imaging has recently been introduced as a promising diagnostic modality in intracranial artery disease. Our aim was to compare high-resolution MR imaging with digital subtraction angiography for the characterization and diagnosis of various intracranial artery diseases. MATERIALS AND METHODS: Thirty-seven patients who had undergone both high-resolution MR imaging and DSA for intracranial artery disease were enrolled in our study (August 2011 to April 2014). The time interval between the high-resolution MR imaging and DSA was within 1 month. The degree of stenosis and the minimal luminal diameter were independently measured by 2 observers in both DSA and high-resolution MR imaging, and the results were compared. Two observers independently diagnosed intracranial artery diseases on DSA and high-resolution MR imaging. The time interval between the diagnoses on DSA and high-resolution MR imaging was 2 weeks. Interobserver diagnostic agreement for each technique and intermodality diagnostic agreement for each observer were acquired. RESULTS: High-resolution MR imaging showed moderate-to-excellent agreement (interclass correlation coefficient = 0.892–0.949; κ = 0.548–0.614) and significant correlations (R = 0.766–892) with DSA on the degree of stenosis and minimal luminal diameter. The interobserver diagnostic agreement was good for DSA (κ = 0.643) and excellent for high-resolution MR imaging (κ = 0.818). The intermodality diagnostic agreement was good (κ = 0.704) for observer 1 and moderate (κ = 0.579) for observer 2, respectively. CONCLUSIONS: High-resolution MR imaging may be an imaging method comparable with DSA for the characterization and diagnosis of various intracranial artery diseases.
- 22 September 2016
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 37 (12) , 2245-2250
Open AccessComparison of High-Resolution MR Imaging and Digital Subtraction Angiography for the Characterization and Diagnosis of Intracranial Artery Disease
BACKGROUND AND PURPOSE: High-resolution MR imaging has recently been introduced as a promising diagnostic modality in intracranial artery disease. Our aim was to compare high-resolution MR imaging with digital subtraction angiography for the characterization and diagnosis of various intracranial artery diseases. MATERIALS AND METHODS: Thirty-seven patients who had undergone both high-resolution MR imaging and DSA for intracranial artery disease were enrolled in our study (August 2011 to April 2014). The time interval between the high-resolution MR imaging and DSA was within 1 month. The degree of stenosis and the minimal luminal diameter were independently measured by 2 observers in both DSA and high-resolution MR imaging, and the results were compared. Two observers independently diagnosed intracranial artery diseases on DSA and high-resolution MR imaging. The time interval between the diagnoses on DSA and high-resolution MR imaging was 2 weeks. Interobserver diagnostic agreement for each technique and intermodality diagnostic agreement for each observer were acquired. RESULTS: High-resolution MR imaging showed moderate-to-excellent agreement (interclass correlation coefficient = 0.892–0.949; κ = 0.548–0.614) and significant correlations (R = 0.766–892) with DSA on the degree of stenosis and minimal luminal diameter. The interobserver diagnostic agreement was good for DSA (κ = 0.643) and excellent for high-resolution MR imaging (κ = 0.818). The intermodality diagnostic agreement was good (κ = 0.704) for observer 1 and moderate (κ = 0.579) for observer 2, respectively. CONCLUSIONS: High-resolution MR imaging may be an imaging method comparable with DSA for the characterization and diagnosis of various intracranial artery diseases.
- 1 January 1997
- Published by The Korean Society of Radiology in Journal of the Korean Radiological Society
- Vol. 37 (6) , 963-968
Experimental Evaluation of Embolic Effect: Pure Glue and Glue-Tungsten Mixture
Suh DC, et al. J Korean Radiol Soc. 1997 Dec;37(6):963-968. https://doi.org/10.3348/jkrs.1997.37.6.963
- 1 January 1997
- Published by The Korean Society of Radiology in Journal of the Korean Radiological Society
- Vol. 37 (6) , 963-968
Experimental Evaluation of Embolic Effect: Pure Glue and Glue-Tungsten Mixture
Suh DC, et al. J Korean Radiol Soc. 1997 Dec;37(6):963-968. https://doi.org/10.3348/jkrs.1997.37.6.963